Results 181 to 190 of about 258,016 (314)

ARL3 Enhances ERα Stability via USP10 Deubiquitination to Promote Endocrine Resistance and Drive Mitochondrial Metabolic Reprogramming in HR+ Breast Cancer

open access: yesAdvanced Science, EarlyView.
This study identifies ADP‐ribosylation factor‐like protein 3 (ARL3) as a novel chaperone that stabilizes estrogen receptor α (ERα) in breast cancer. ARL3 promotes tumor growth by recruiting USP10 to remove ubiquitin chains from ERα, preventing its degradation.
Han Li   +14 more
wiley   +1 more source

Prognostic significance of steroid hormone receptors (ER and PR) in primary operable breast cancer [PDF]

open access: yesArchive of Oncology, 2002
Kanjer Ksenija   +4 more
doaj   +1 more source

SLC6A14 Drives Mitochondrial Fusion and Oxidative Phosphorylation to Promote Cancer Stemness and Early‐Onset of Breast Cancer

open access: yesAdvanced Science, EarlyView.
Elevated levels of the plasticizer DEHP associate with earlier breast cancer diagnosis. DEHP enhances glutamine‐powered energy production via the transporter SLC6A14 and pushes mitochondria toward fusion, driving tumor initiation by boosting cancer stemness. Blocking SLC6A14 lowers stemness, slows tumors, and improves chemotherapy response.
Dai‐Wei Hu   +15 more
wiley   +1 more source

Enhanced Selenium Supplement Extends Lifespan and Delays Multi‐Organs Aging by Regulating the Sik1 Pathway Through Maintaining Calcium Homeostasis

open access: yesAdvanced Science, EarlyView.
Aging involves physiological decline and heightened disease susceptibility, necessitating effective interventions. Redox‐responsive selenium‐loaded nanoparticles (SeMSNs) are developed, which delay cellular senescence by reducing oxidative stress and senescence markers (p16/p21). In aged mice, SeMSNs extend lifespan, improve organ function, and restore
Yang Yu   +15 more
wiley   +1 more source

Long‐term prognosis is associated with residual disease after neoadjuvant systemic therapy but not with initial nodal status

open access: yesBJS (British Journal of Surgery), EarlyView., 2020
This long‐term follow‐up study determined survival rates in a Swedish national cohort of 417 patients with breast cancer who all had neoadjuvant systemic therapy (NAST). Sentinel lymph node biopsy (SLNB) was performed before NAST in clinically node‐negative and after NAST in clinically node‐positive patients.
L. Zetterlund   +4 more
wiley   +1 more source

Genetically Engineered Light‐Responsive In Situ Hydrogels for Immunomodulation and Multimodal Therapy in Metastatic Triple‐Negative Breast Cancer

open access: yesAdvanced Science, EarlyView.
Cysteine‐tagged silk‐elastin‐like proteins, a family of tri‐block chimeric proteins that consist of a photothermal agent binding motif, silk motif, and elastin motif is developed to form a responsive in situ hydrogel for late‐stage and metastatic triple‐negative breast cancer.
Xinchen Shen   +11 more
wiley   +1 more source

Emerging Nanozyme Strategies for Precision Breast Cancer Treatment

open access: yesAdvanced Science, EarlyView.
Different types of nanozymes‐mediated chemotherapy, photothermal therapy, immunotherapy, and multiple combined therapies for the effective treatment of breast cancer. Abstract Breast cancer, the most common malignant tumor among women worldwide, poses a significant challenge to public health due to its high incidence and mortality rates.
Jian Zang   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy